Running a Weight Loss Clinic on GLP-1s: What Every Provider Needs to Know Right Now

Are you a provider running — or thinking about starting — a weight loss clinic using GLP-1 medications? In this episode of The Real World Provider, Danni Owens, FNP-BC, breaks down everything healthcare providers need to know about semaglutide and tirzepatide in 2026. From the FDA's oral Wegovy approval to the compounding pharmacy legal battles, prescribing authority by state, clinical protocols, cash-pay pricing models, and where the GLP-1 market is heading — this is the real-world guide to building a sustainable weight loss practice with GLP-1 receptor agonists.

Whether you're an NP, PA, or MD looking to add GLP-1 prescribing to your clinic, or you're already offering weight management services and want to stay ahead of the regulatory changes, this episode covers it all.

Topics include: semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), 503A vs. 503B compounding pharmacies, FDA shortage list updates, patient selection criteria, titration protocols, side effect management, cash-pay clinic models, oral GLP-1 medications, insurance coverage trends, and how to compete with telehealth and retail clinics.